Ovarian Cancer Causes
Ovarian Cancer Causes
Ovarian cancer has no single cause, but it has a clear risk architecture: inherited DNA-repair variants (BRCA1/2 above all), the number of lifetime ovulations, and endometriosis. The same architecture points the other way too — things that suppress ovulation lower the risk.
BRCA1 and BRCA2
BRCA1 and BRCA2 are the genes that repair DNA double-strand breaks; a variant in either leaves cells to repair by error-prone routes. Inherited in an autosomal dominant pattern, BRCA variants raise lifetime ovarian cancer risk substantially alongside breast cancer risk, and they account for a substantial minority of high-grade serous cases — which makes ovarian cancer one of the common cancers with a genuinely large hereditary fraction.
The same defect is the treatment opportunity. A tumour already coping with defective DNA repair is precisely the tumour that PARP-inhibitor maintenance holds in check — the genetics of risk and the genetics of treatment are the same genetics. This is why germline testing is offered for every epithelial ovarian cancer: the result serves the patient (maintenance eligibility), the family (cascade testing and risk reduction), and the follow-up plan at once.
Beyond BRCA: HRD
The DNA-repair pathway has more participants than BRCA1 and BRCA2, and a tumour can be defective across the whole homologous recombination system without an inherited variant — through epigenetic silencing or other acquired defects. Tumour-level HRD testing identifies this wider group, and it matters because they respond to platinum chemotherapy and qualify for PARP maintenance in defined situations, just as BRCA carriers do.
The practical point: a negative germline BRCA result is not the end of the genetic story. Tumour testing can find acquired BRCA variants and HRD status, and together the blood and tumour results decide the maintenance question. Both are arranged at diagnosis, on the tissue and blood already collected.
Family history
Family history matters in a structured way, not as a vague alarm. The patterns that earn a genetics referral: ovarian cancer in a close relative at any age, breast cancer diagnosed young (under roughly 45), male breast cancer, multiple relatives with breast or ovarian cancer on one side, or Ashkenazi Jewish ancestry with either cancer in the family. In such families, cascade testing identifies who carries the variant — and who does not, which is equally valuable information.
For a woman with ovarian cancer herself, the family history is part of the same conversation: her result may explain a pattern across the family, and her relatives' testing follows from her own. Where no variant is found, a strong family history still justifies earlier and more structured surveillance than average risk.
Ovulation, age and hormones
The ovulation–ovulation-count hypothesis underlies several risk facts. Each ovulation breaks the ovarian surface and requires a repair that can go wrong; the more lifetime ovulations, the more repair events. This is why risk rises with age (most epithelial cases after menopause), with nulliparity and late first childbirth (more uninterrupted cycles), and conversely why pregnancy, breastfeeding and oral contraceptive use lower the risk — each suppresses ovulation, and the combined pill's protective effect persists for years after stopping.
Hormone therapy after menopause is reported as a modest risk factor that recedes after stopping; fertility stimulation without pregnancy is debated and not established as a cause. The architecture is symmetrical and worth knowing both ways: the same biology that raises risk also offers the risk-reducing levers described on the prevention page.
Endometriosis
Endometriosis — endometrial-type tissue outside the uterus — is a recognized risk factor for two epithelial subtypes, clear cell and endometrioid carcinoma. The association is real but should be read calmly: the large majority of women with endometriosis never develop ovarian cancer, and the absolute risk remains small; surveillance of endometriosis is not a screening programme.
The practical implications: women with longstanding endometriosis and a new or changing adnexal mass deserve prompt ultrasound assessment; and clear cell histology in a tumour changes the chemotherapy conversation, because it is less platinum-sensitive than high-grade serous disease. Type, again, is what drives the plan.
What does not cause it
Ovarian cancer collects its share of folk causes. The evidence:
- Fertility treatment is not established as a cause — the debate concerns stimulation without pregnancy; IVF with resulting pregnancy is not associated with increased risk in cohort data.
- Talc is not an established cause — modern talc products free of asbestos have not been shown to raise risk in large analyses, though the question generated decades of litigation.
- Intrauterine devices do not cause it — IUD use is associated with reduced risk in most studies.
- Cysts are not cancers-in-waiting — the vast majority of simple ovarian cysts are benign and resolve; only specific complex appearances need excision.
- A diagnosis does not indict lifestyle — beyond the factors above, ovarian cancer is not attributed to diet, stress or personal habits.
These clarifications matter because they redirect attention to what works: the genetic conversation for families with a pattern, ovulation-suppressing choices where appropriate, and symptom awareness for everyone else.